B

Bioton SA
WSE:BIO

Watchlist Manager
Bioton SA
WSE:BIO
Watchlist
Price: 2.81 PLN -3.77% Market Closed
Market Cap: 241.3m PLN
Have any thoughts about
Bioton SA?
Write Note

Bioton SA
Investor Relations

BIOTON SA engages in the manufacture and production of medicine and pharmaceutical substances. The company is headquartered in Warsaw, Woj. Mazowieckie and currently employs 371 full-time employees. The company went IPO on 2005-03-16. The firm is engaged in research, development and wholesale trade of pharmaceutical and biotechnological products. The firm's portfolio consists of oral hypoglycemic drugs (metformin and glimepride) as well as recombinant human insulin in pharmaceutical substance form and for injections. Additionally, the Company provides advertising services. As of December 31, 2011, the Company formed a capital group and operated through its subsidiaries, including BIOTON TRADE Sp. z o.o., Mindar Holdings Ltd, Germonta Holdings Ltd, Tricel SA, SciGen Ltd and BioPartners Holdings AG, among others. On June 12, 2014, it sold a 50% stake in Copernicus Sp. z o.o.

Show more

Earnings Calls

No Earnings Calls Available

Management

Mr. Jeremy Launders
CEO & President of the Management Board
No Bio Available
Mr. Adam Tomasz Polonek
Member of Management Board
No Bio Available
Ms. Anna Grabowska
Senior Finance Manager
No Bio Available
Mr. Michal Deptuch
Operations Director
No Bio Available
Renata Prokopczyk
Chief Accountant
No Bio Available
Ms. Kamila Musnicka
Director of Legal Department
No Bio Available
Mr. Mateusz Patryk Kosecki
Head of Biolek Business Unit & CEO of Biolek Sp. Z O.O.
No Bio Available

Contacts

Address
WOJ. MAZOWIECKIE
Warsaw
ul. Staroscinska 5
Contacts
+48227214000
bioton.com